CL2012000788A1 - Anticuerpo aislado que se une a fibrina o fibronogeno; metodo para aliviar un sintoma de una patologia asociada con la union de mac-1 a fibrina o fibrinogeno; composicion farmaceutica; kit; vector; celula; metodo para generar anticuerpo; metodo para analizar un ligando que se une a un receptor mac-1. - Google Patents
Anticuerpo aislado que se une a fibrina o fibronogeno; metodo para aliviar un sintoma de una patologia asociada con la union de mac-1 a fibrina o fibrinogeno; composicion farmaceutica; kit; vector; celula; metodo para generar anticuerpo; metodo para analizar un ligando que se une a un receptor mac-1.Info
- Publication number
- CL2012000788A1 CL2012000788A1 CL2012000788A CL2012000788A CL2012000788A1 CL 2012000788 A1 CL2012000788 A1 CL 2012000788A1 CL 2012000788 A CL2012000788 A CL 2012000788A CL 2012000788 A CL2012000788 A CL 2012000788A CL 2012000788 A1 CL2012000788 A1 CL 2012000788A1
- Authority
- CL
- Chile
- Prior art keywords
- fibrin
- mac
- binds
- antibody
- fibrinogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Abstract
Anticuerpo aislado que se une a fibrina o fibronógeno; método para aliviar un síntoma de una patología asociada con la unión de MAC-1 a fibrina o fibrinógeno; composición farmacéutica; kit; vector; célula; método para generar anticuerpo; método para analizar un ligando que se une a un receptor MAC-1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24801409P | 2009-10-02 | 2009-10-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2012000788A1 true CL2012000788A1 (es) | 2012-09-14 |
Family
ID=43826649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2012000788A CL2012000788A1 (es) | 2009-10-02 | 2012-03-30 | Anticuerpo aislado que se une a fibrina o fibronogeno; metodo para aliviar un sintoma de una patologia asociada con la union de mac-1 a fibrina o fibrinogeno; composicion farmaceutica; kit; vector; celula; metodo para generar anticuerpo; metodo para analizar un ligando que se une a un receptor mac-1. |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US8877195B2 (es) |
| EP (1) | EP2483416B1 (es) |
| JP (1) | JP5883389B2 (es) |
| KR (1) | KR101793221B1 (es) |
| CN (1) | CN102575277B (es) |
| AR (1) | AR078490A1 (es) |
| AU (1) | AU2010300559B2 (es) |
| BR (1) | BR112012008370B8 (es) |
| CA (1) | CA2774256C (es) |
| CL (1) | CL2012000788A1 (es) |
| CO (1) | CO6440561A2 (es) |
| CR (1) | CR20120127A (es) |
| CY (1) | CY1118540T1 (es) |
| DK (1) | DK2483416T3 (es) |
| DO (1) | DOP2012000089A (es) |
| EA (1) | EA023477B1 (es) |
| ES (1) | ES2614939T3 (es) |
| GE (2) | GEP20166458B (es) |
| GT (1) | GT201200096A (es) |
| HK (1) | HK1168871A1 (es) |
| HR (1) | HRP20170110T1 (es) |
| HU (1) | HUE031571T2 (es) |
| IL (1) | IL218621B (es) |
| IN (1) | IN2012DN03154A (es) |
| LT (1) | LT2483416T (es) |
| MA (1) | MA33704B1 (es) |
| MX (1) | MX2012003811A (es) |
| MY (1) | MY159359A (es) |
| NZ (1) | NZ598770A (es) |
| PL (1) | PL2483416T3 (es) |
| PT (1) | PT2483416T (es) |
| SI (1) | SI2483416T1 (es) |
| SM (1) | SMT201700083B (es) |
| TN (1) | TN2012000149A1 (es) |
| TW (1) | TWI511741B (es) |
| UA (1) | UA108860C2 (es) |
| WO (1) | WO2011041518A1 (es) |
| ZA (1) | ZA201202227B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8771693B2 (en) | 2009-10-27 | 2014-07-08 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
| US10485780B2 (en) | 2011-03-14 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the treatment of proliferative disorders |
| US10487114B2 (en) | 2011-04-27 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof |
| US9439884B2 (en) | 2011-05-26 | 2016-09-13 | Beth Israel Deaconess Medical Center, Inc. | Methods for the treatment of immune disorders |
| US9730941B2 (en) | 2012-06-07 | 2017-08-15 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the inhibition of Pin1 |
| US9688747B2 (en) | 2013-03-15 | 2017-06-27 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
| US10451611B2 (en) | 2014-01-11 | 2019-10-22 | The J. David Gladstone Institute | Compositions and methods for in vitro assays of fibrin activity |
| WO2016011268A1 (en) | 2014-07-17 | 2016-01-21 | Beth Israel Deaconess Medical Center, Inc. | Atra for modulating pin1 activity and stability |
| US10351914B2 (en) | 2014-07-17 | 2019-07-16 | Beth Israel Deaconess Medical Center, Inc. | Biomarkers for Pin1-associated disorders |
| US10548864B2 (en) | 2015-03-12 | 2020-02-04 | Beth Israel Deaconess Medical Center, Inc. | Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions |
| SG11201910113PA (en) * | 2017-05-02 | 2019-11-28 | Nat Cancer Center Japan | Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate |
| KR20220161374A (ko) * | 2020-03-31 | 2022-12-06 | 국립연구개발법인 고쿠리츠간켄큐센터 | 피브린에 결합하는 항체 및 당해 항체를 포함하는 의약 조성물 |
| US20240059761A1 (en) * | 2020-12-16 | 2024-02-22 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David | Use of fibrin-targeting immunotherapy to reduce Coronavirus pathogenesis |
| WO2022159776A1 (en) * | 2021-01-21 | 2022-07-28 | Therini Bio, Inc. | Antibodies which bind human fibrin and methods of use |
| CN117794948A (zh) * | 2021-06-18 | 2024-03-29 | 特里尼生物公司 | 结合人纤维蛋白或纤维蛋白原γC结构域的抗体及其使用方法 |
| WO2022266539A2 (en) * | 2021-06-18 | 2022-12-22 | Therini Bio, Inc. | ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE |
| WO2024044583A1 (en) * | 2022-08-22 | 2024-02-29 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Human anti-fibrin antibodies and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030031675A1 (en) * | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
| KR101456770B1 (ko) * | 2004-05-27 | 2014-10-31 | 크루셀 홀란드 비.브이. | 광견병 바이러스를 중화시킬 수 있는 결합 분자 및 그 용도 |
| US7807645B2 (en) * | 2005-09-23 | 2010-10-05 | The Regents Of The University Of California | Method of treating degenerative disorders of the nervous system by administration of fibrinogen fragment |
-
2010
- 2010-09-30 WO PCT/US2010/050873 patent/WO2011041518A1/en active Application Filing
- 2010-09-30 SI SI201031390A patent/SI2483416T1/sl unknown
- 2010-09-30 EA EA201270416A patent/EA023477B1/ru unknown
- 2010-09-30 AU AU2010300559A patent/AU2010300559B2/en active Active
- 2010-09-30 JP JP2012532307A patent/JP5883389B2/ja active Active
- 2010-09-30 NZ NZ598770A patent/NZ598770A/en unknown
- 2010-09-30 CA CA2774256A patent/CA2774256C/en active Active
- 2010-09-30 CN CN201080046037.8A patent/CN102575277B/zh active Active
- 2010-09-30 LT LTEP10821238.2T patent/LT2483416T/lt unknown
- 2010-09-30 DK DK10821238.2T patent/DK2483416T3/en active
- 2010-09-30 GE GEAP201013232A patent/GEP20166458B/en unknown
- 2010-09-30 UA UAA201203044A patent/UA108860C2/ru unknown
- 2010-09-30 ES ES10821238.2T patent/ES2614939T3/es active Active
- 2010-09-30 HU HUE10821238A patent/HUE031571T2/en unknown
- 2010-09-30 GE GEAP201012676A patent/GEP20156214B/en unknown
- 2010-09-30 MX MX2012003811A patent/MX2012003811A/es active IP Right Grant
- 2010-09-30 PL PL10821238T patent/PL2483416T3/pl unknown
- 2010-09-30 PT PT108212382T patent/PT2483416T/pt unknown
- 2010-09-30 KR KR1020127011293A patent/KR101793221B1/ko active IP Right Grant
- 2010-09-30 MY MYPI2012001408A patent/MY159359A/en unknown
- 2010-09-30 EP EP10821238.2A patent/EP2483416B1/en active Active
- 2010-09-30 BR BR112012008370A patent/BR112012008370B8/pt active IP Right Grant
- 2010-10-01 TW TW099133559A patent/TWI511741B/zh active
- 2010-10-01 AR ARP100103578A patent/AR078490A1/es not_active Application Discontinuation
-
2012
- 2012-03-14 IL IL218621A patent/IL218621B/en not_active IP Right Cessation
- 2012-03-16 CR CR20120127A patent/CR20120127A/es unknown
- 2012-03-20 US US13/425,020 patent/US8877195B2/en active Active
- 2012-03-27 ZA ZA2012/02227A patent/ZA201202227B/en unknown
- 2012-03-29 DO DO2012000089A patent/DOP2012000089A/es unknown
- 2012-03-30 GT GT201200096A patent/GT201200096A/es unknown
- 2012-03-30 CL CL2012000788A patent/CL2012000788A1/es unknown
- 2012-03-30 TN TNP2012000149A patent/TN2012000149A1/en unknown
- 2012-04-12 IN IN3154DEN2012 patent/IN2012DN03154A/en unknown
- 2012-04-18 CO CO12064155A patent/CO6440561A2/es active IP Right Grant
- 2012-04-30 MA MA34824A patent/MA33704B1/fr unknown
- 2012-09-27 HK HK12109512.6A patent/HK1168871A1/zh unknown
-
2017
- 2017-01-23 HR HRP20170110TT patent/HRP20170110T1/hr unknown
- 2017-01-30 CY CY20171100132T patent/CY1118540T1/el unknown
- 2017-02-08 SM SM201700083T patent/SMT201700083B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2012000788A1 (es) | Anticuerpo aislado que se une a fibrina o fibronogeno; metodo para aliviar un sintoma de una patologia asociada con la union de mac-1 a fibrina o fibrinogeno; composicion farmaceutica; kit; vector; celula; metodo para generar anticuerpo; metodo para analizar un ligando que se une a un receptor mac-1. | |
| CU20190109A7 (es) | Moléculas de anticuerpo que se unen a cd73 | |
| CL2013000843A1 (es) | Anticuerpo aislado o fragmento de union a antigeno del mismo que se une especificamente a cd48 humano y bloquea la interaccion entre cd48 humano y un receptor de cd48; composicion farmaceutica que lo comprende; y su uso. | |
| GT200900035A (es) | Anticuerpo especifico prlr y sus usos | |
| CL2012002884A1 (es) | Polipeptido que comprende un dominio decimo de fibronectina de tipo iii que se unen a la proteina covertasa subtilisina kexina tipo q ( pcsk9); composicion farmacéutica que comprende dicho polipeptido. | |
| PA8850201A1 (es) | Combinaciones antitumorales que contienen anticuerpos | |
| CL2012003375A1 (es) | Anticuerpo monoclonal que se une a enzima ariloxialcanoato dioxigenasa (aad-12); linea celular de hibridomas que produce dicho anticuerpo; metodos para detectar la presencia de la enzima aad-12; metodo para la deteccion cuantitativa de una enzima aad-12. | |
| BR112014026755A2 (pt) | anticorpos contra claudin 18.2 úteis no diagnóstico de câncer | |
| PA8850101A1 (es) | Combinaciones antitumorales que contienen anticuerpos | |
| CL2013002203A1 (es) | Molecula de union a antigeno (abm) que se une al antigeno carcinoembrionario humano (cea) unido a membrana; anticuerpo que se une a cea unido a membrana; polinucleotido que los codifica; vector; celula huesped; composicion que comprende al abm o al anticuerpo; y su uso para tratar un cancer que expresa niveles anormales de cea. | |
| UA108199C2 (uk) | АНТИТІЛО ПРОТИ α5β1 І ЙОГО ЗАСТОСУВАННЯ | |
| CL2011002380A1 (es) | Anticuerpo multiespecifico que comprende un anticuerpo de longitud completa que se une especificamente a un primer antigeno y uno o mas fragmentos fab de cadena sencilla que se unen a uno o mas antigenos, acido nucleico que lo codifica; y composicion farmaceutica que lo comprende. | |
| ECSP12012307A (es) | Proteínas de unión a il-1 | |
| AR069775A1 (es) | Anticuerpos bivalentes biespecificos | |
| AR060241A1 (es) | Composiciones y metodos de uso para anticuerpos de c-met | |
| CL2014001123A1 (es) | Anticuerpos anti-il 36r; composicion farmaceutica que lo contiene; polinucleotido aislado que codifica el anticuerpo; metodo para la produccion del anticuerpo; kit de diagnostico que lo contiene. | |
| EP2544540A4 (en) | LENALIDOMIDE AND THALIDOMIDE IMMUNASSAYS | |
| EA201000717A1 (ru) | Молекулы и способы, предназначенные для модуляции компонента системы комплемента | |
| CR20110559A (es) | Anticuerpos específicos para cadherina-17 | |
| CL2014002590A1 (es) | Anticuerpos que une a los ligandos calidina y des-arg10-calidina del receptor b1 de bradicinina; metodo de produccion del anticuerpo; composicion farmaceutica que contiene el anticuerpo; metodo de uso del anticuerpo. | |
| MX365387B (es) | Anticuerpos específicos de polipéptido amiloide de islote humano (hiapp) y sus usos. | |
| BR112013007946A2 (pt) | polipeptídeos hemaglutinina, reagentes e métodos relacionados aos mesmos. | |
| MX2009004167A (es) | Anticuerpos que enlazan epitopos cxcr7. | |
| EA201291065A1 (ru) | Антитела против vla-4 | |
| TR201819828T4 (tr) | Anti-fosfolipaz d4 antikoru. |